- Title
- Influence of age on outcome in patients with pulmonary arterial hypertension
- Creator
- Kodur, Sreekanth; Ahmad, Waheed; Heittarachi, Melanie; Reeves, Glenn; Attia, John; Barker, Daniel; Collins, Nicholas
- Relation
- Heart Lung and Circulation Vol. 24, Issue 7, p. 719-723
- Publisher Link
- http://dx.doi.org/10.1016/j.hlc.2015.01.012
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2015
- Description
- Background: The development of effective orally administered medical therapy for pulmonary arterial hypertension (PAH) has made a significant impact on outcome in patients with PAH. Identification of patient groups likely to derive optimal benefit is important, given cost and potential side effects; the clinical effectiveness of these therapies in older patients with PAH is unclear as the presence of co-morbidity may limit benefits of therapy. Aims: We evaluated the epidemiology of PAH in a contemporary cohort to assess the influence of age on long-term outcome using PAH-specific therapies. Results: A total of 119 patients (88% female; mean age 65±12 years) were reviewed, comprising 52% with underlying connective tissue disease. Bosentan was the PAH specific agent most frequently used. The baseline 6MWT distance in the entire cohort was 304m with age associated with a significant decline in 6MWT. Conclusions: In a large cohort of patients treated with PAH-specific therapies, patients less than 55 years of age showed improvement in 6MWT with older patients demonstrating stabilisation or decline.
- Subject
- pulmonary arterial hypertension; endothelin receptor antagonist; phosphodiesterase inhibitor; right heart failure; cardiac transplant
- Identifier
- http://hdl.handle.net/1959.13/1336913
- Identifier
- uon:27725
- Identifier
- ISSN:1443-9506
- Language
- eng
- Reviewed
- Hits: 6382
- Visitors: 6358
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|